Objective:To explore the outcome and side-effects in patients with multiple myeloma treated with velcade and combined chemotherapy. Methods: 6 patients with multiple myeloma were treated with the combination of velcad...Objective:To explore the outcome and side-effects in patients with multiple myeloma treated with velcade and combined chemotherapy. Methods: 6 patients with multiple myeloma were treated with the combination of velcade and dexamethasone or DVD (V-DVD regimen) chemotherapy. Results: 6 patients responded to treatment. 4 patients achieved complete remission (CR), 1 achieved partial remission (PR) and 1 achieved micro responded (MR). Major toxicities consisted of peripheral neuropathy, thrombocytopenia and hepatic impairment. Conclusion: Velcade combined chemotherapy is an effective and safety treatment for patients with multiple myeloma.展开更多
脑胶质瘤是成人中枢神经系统中最常见的恶性肿瘤之一,尤其是恶性程度高的胶质母细胞瘤,其预后极差,传统的手术、放疗和化疗等治疗方式效果有限。蛋白酶体抑制剂作为一种新兴的抗肿瘤治疗方式,通过抑制细胞蛋白降解的通路,干扰细胞内蛋...脑胶质瘤是成人中枢神经系统中最常见的恶性肿瘤之一,尤其是恶性程度高的胶质母细胞瘤,其预后极差,传统的手术、放疗和化疗等治疗方式效果有限。蛋白酶体抑制剂作为一种新兴的抗肿瘤治疗方式,通过抑制细胞蛋白降解的通路,干扰细胞内蛋白质稳态,进而诱导肿瘤细胞死亡。本文综述了蛋白酶体抑制剂在脑胶质瘤治疗中的作用机制、临床前和临床研究进展,并探讨了其应用前景和面临的挑战。Gliomas are one of the most common malignant tumors in the adult central nervous system, especially highly malignant glioblastomas, which have a very poor prognosis. Traditional treatments such as surgery, radiotherapy, and chemotherapy have limited effectiveness. Proteasome inhibitors, as an emerging anti-tumor therapy, interfere with intracellular protein homeostasis by inhibiting the pathway of cellular protein degradation, thereby inducing tumor cell death. This article reviews the mechanism of action, preclinical and clinical research progress of proteasome inhibitors in the treatment of glioblastoma, and explores their application prospects and challenges.展开更多
文摘Objective:To explore the outcome and side-effects in patients with multiple myeloma treated with velcade and combined chemotherapy. Methods: 6 patients with multiple myeloma were treated with the combination of velcade and dexamethasone or DVD (V-DVD regimen) chemotherapy. Results: 6 patients responded to treatment. 4 patients achieved complete remission (CR), 1 achieved partial remission (PR) and 1 achieved micro responded (MR). Major toxicities consisted of peripheral neuropathy, thrombocytopenia and hepatic impairment. Conclusion: Velcade combined chemotherapy is an effective and safety treatment for patients with multiple myeloma.
文摘脑胶质瘤是成人中枢神经系统中最常见的恶性肿瘤之一,尤其是恶性程度高的胶质母细胞瘤,其预后极差,传统的手术、放疗和化疗等治疗方式效果有限。蛋白酶体抑制剂作为一种新兴的抗肿瘤治疗方式,通过抑制细胞蛋白降解的通路,干扰细胞内蛋白质稳态,进而诱导肿瘤细胞死亡。本文综述了蛋白酶体抑制剂在脑胶质瘤治疗中的作用机制、临床前和临床研究进展,并探讨了其应用前景和面临的挑战。Gliomas are one of the most common malignant tumors in the adult central nervous system, especially highly malignant glioblastomas, which have a very poor prognosis. Traditional treatments such as surgery, radiotherapy, and chemotherapy have limited effectiveness. Proteasome inhibitors, as an emerging anti-tumor therapy, interfere with intracellular protein homeostasis by inhibiting the pathway of cellular protein degradation, thereby inducing tumor cell death. This article reviews the mechanism of action, preclinical and clinical research progress of proteasome inhibitors in the treatment of glioblastoma, and explores their application prospects and challenges.
